The first platform combining FDA decisions, clinical trials, state laws, stock prices, and earnings — every angle of the GLP-1 industry, in one place.

Why this exists

Information is power. Also, it's money.

The same forces moving your medication are moving these stocks. A PBM formulary change at Caremark drops CVS 4%. An FDA approval for a competitor sends Lilly up 6%. A congressional bill on coverage moves three companies at once. A state compounding ruling can end an entire business line overnight.

Most GLP-1 stock coverage is written by people who have never taken a dose. They miss what patients see in real time. We built this for everyone watching this industry — patients, investors, journalists, healthcare workers — and for anyone who needs the full picture in one place.